Gender differences in the risk of ischemic stroke and peripheral embolism in atrial brillation: the AnTicoagulation and Risk factors In Atrial brillation (ATRIA) study. Circulation. 2005;112(12): 1687-1691. 46. Healey JS, Hart RG, Pogue J, et al. Risks and bene ts of oral anticoagulation compared with clopidogrel plus aspi- rin in patients with atrial brillation according to stroke risk: the atrial brillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W). Stroke. 2008;39(5):1482-1486. 47. Arima H, Hart RG, Colman S, et al; PROGRESS Colla- borative Group. Perindopril-based blood pressure-lowering reduces major vascular events in patients with atrial bril- lation and prior stroke or transient ischemic attack. Stroke. 2005;36(10):2164-2169. 48. Lip GY, Frison L, Grind M; SPORTIF Investigators. Effect of hypertension on anticoagulated patients with atrial bril- lation. Eur Heart J. 2007;28(6):752-759. 49. Eckman MH, Singer DE, Rosand J, Greenberg SM. Moving the tipping point: the decision to anticoagulate patients with atrial brillation. Circ Cardiovasc Qual Outcomes. 2011; 4(1):14-21. 50. National Collaborating Centre for Chronic Conditions. Atrial brillation: national clinical guideline for manage- ment in primary and secondary care. London, England: Royal College of Physicians; 2006:104. Available at: http:// www.nice.org.uk/nicemedia/live/10982/30055/30055.pdf. Accessed November 22, 2011. 51. Singer DE, Chang Y, Fang MC, et al. The net clinical bene t of warfarin anticoagulation in atrial brillation. Ann Intern Med. 2009;151(5):297-305. 52. Hart RG, Pearce LA. Current status of stroke risk strat- i cation in patients with atrial brillation. Stroke. 2009; 40(7):2607-2610. 53. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial brilla- tion: The Euro Heart Survey. Chest. 2010;138(5):1093-1100. 54. van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Bri t E. Bleeding complications in oral anticoagulant therapy. An anal- ysis of risk factors. 